-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Zejing Pharmaceutical announced on the evening of November 25 that the company disclosed plans to raise approximately 2.
863 billion yuan in additional funds for new drug research and development, production center construction and supplementary liquidity projects
.
It is reported that this fundraising will further enhance the company's comprehensive competitiveness in the field of anti-tumor therapy, enrich the pipeline of products under research, and expand the breadth and depth of research and development in small molecule innovative drugs and innovative antibody products
.
On the same day, Simcere Pharmaceutical Co.
, Ltd.
, Sidi Medicine, and Corning Jereh Biopharmaceuticals jointly announced that the PD-L1 subcutaneous injection preparation "Envida", which is a three-party strategic cooperation, has been approved for marketing, and is suitable for unresectable or highly unstable metastatic microsatellites.
(MSI-H) or mismatch repair gene defect (dMMR) in the treatment of adult patients with advanced solid tumors
.
On November 22, it was reported that Huahui Anjian’s Class 1 new drug HH-101 injection was approved for the first time for clinical trials, and the indication was approved for advanced solid tumor trials
.
.
.
.
.
.
.
In just a few days, news about the clinical approval, listing and capital increase of oncology drugs continued to spread, which will be a great boon for the cancer patients behind it
.
Data show that the number of cancers in China in 2020 is about 4.
568 million, and it is expected that the number of new cancers in China will increase to 5.
2 million and 5.
8 million in 2025 and 2030, respectively
.
In recent years, due to a large number of cancer patients stimulating industry demand, coupled with the increase in residents' disposable income and the expansion of medical reimbursement, the scale of China's oncology drug market has continued to expand
.
Data show that the size of China's oncology drug market has increased from US$19.
2 billion in 2016 to US$30.
4 billion in 2020, accounting for 9.
4% and 13.
6% of the Chinese pharmaceutical market, respectively, with a compound annual growth rate of 12.
1%
.
The Chinese oncology drug market is expected to reach USD 37.
5 billion in 2021, accounting for 14.
1% of the Chinese pharmaceutical market
.
In the face of the huge market pie, major pharmaceutical companies are pouring into the track one after another, including Hengrui Pharmaceuticals, Fosun Pharmaceuticals, Betta Pharmaceuticals, Livzon Group, and Kelun Pharmaceuticals
.
With the continuous R&D of these pharmaceutical companies and the accelerated review of new drugs, the number of oncology drugs on the domestic market continues to increase
.
At present, clinical anti-tumor drugs mainly include chemotherapeutics, targeted therapy drugs, biological agents, immune drugs, and anti-tumor Chinese medicines
.
In recent years, with the increase of capital, the influx of talents, and policy support, the proportion of innovative drugs such as small molecule targeted drugs, large molecule targeted drugs, and immunotherapy has gradually increased
.
From the perspective of the number of targets related to tumor treatment, the relatively high proportions include PD-(L)1, VEGFR, EGFR, HER2 and so on
.
Among them, the research and development of PD-(L)1 has been in full swing in recent years.
At least 8 PD-1/PD-L1 monoclonal antibodies have been approved in China, 4 of which have entered medical insurance, and many have entered the clinical development stage.
It is very crowded, the competition is fierce, and the domestic market will become saturated in the future
.
In the face of fierce market competition, major pharmaceutical companies have also adopted strategies such as expanding indications, accelerating clinical development, and differentiated layout to enhance product competitiveness
.
Industrial Securities stated in its research report that in the future, China's innovative drug research and development will require the participation of various pharmaceutical companies
.
With the development and maturity of more important targets and technology platforms, on the basis of in-depth layout, more competitive R&D needs to be done-with "differentiation" and "unmet clinical needs" as the two main lines, from In the early stage of R&D layout, fierce homogenization competition was avoided
.
863 billion yuan in additional funds for new drug research and development, production center construction and supplementary liquidity projects
.
It is reported that this fundraising will further enhance the company's comprehensive competitiveness in the field of anti-tumor therapy, enrich the pipeline of products under research, and expand the breadth and depth of research and development in small molecule innovative drugs and innovative antibody products
.
On the same day, Simcere Pharmaceutical Co.
, Ltd.
, Sidi Medicine, and Corning Jereh Biopharmaceuticals jointly announced that the PD-L1 subcutaneous injection preparation "Envida", which is a three-party strategic cooperation, has been approved for marketing, and is suitable for unresectable or highly unstable metastatic microsatellites.
(MSI-H) or mismatch repair gene defect (dMMR) in the treatment of adult patients with advanced solid tumors
.
On November 22, it was reported that Huahui Anjian’s Class 1 new drug HH-101 injection was approved for the first time for clinical trials, and the indication was approved for advanced solid tumor trials
.
.
.
.
.
.
.
In just a few days, news about the clinical approval, listing and capital increase of oncology drugs continued to spread, which will be a great boon for the cancer patients behind it
.
Data show that the number of cancers in China in 2020 is about 4.
568 million, and it is expected that the number of new cancers in China will increase to 5.
2 million and 5.
8 million in 2025 and 2030, respectively
.
In recent years, due to a large number of cancer patients stimulating industry demand, coupled with the increase in residents' disposable income and the expansion of medical reimbursement, the scale of China's oncology drug market has continued to expand
.
Data show that the size of China's oncology drug market has increased from US$19.
2 billion in 2016 to US$30.
4 billion in 2020, accounting for 9.
4% and 13.
6% of the Chinese pharmaceutical market, respectively, with a compound annual growth rate of 12.
1%
.
The Chinese oncology drug market is expected to reach USD 37.
5 billion in 2021, accounting for 14.
1% of the Chinese pharmaceutical market
.
In the face of the huge market pie, major pharmaceutical companies are pouring into the track one after another, including Hengrui Pharmaceuticals, Fosun Pharmaceuticals, Betta Pharmaceuticals, Livzon Group, and Kelun Pharmaceuticals
.
With the continuous R&D of these pharmaceutical companies and the accelerated review of new drugs, the number of oncology drugs on the domestic market continues to increase
.
At present, clinical anti-tumor drugs mainly include chemotherapeutics, targeted therapy drugs, biological agents, immune drugs, and anti-tumor Chinese medicines
.
In recent years, with the increase of capital, the influx of talents, and policy support, the proportion of innovative drugs such as small molecule targeted drugs, large molecule targeted drugs, and immunotherapy has gradually increased
.
From the perspective of the number of targets related to tumor treatment, the relatively high proportions include PD-(L)1, VEGFR, EGFR, HER2 and so on
.
Among them, the research and development of PD-(L)1 has been in full swing in recent years.
At least 8 PD-1/PD-L1 monoclonal antibodies have been approved in China, 4 of which have entered medical insurance, and many have entered the clinical development stage.
It is very crowded, the competition is fierce, and the domestic market will become saturated in the future
.
In the face of fierce market competition, major pharmaceutical companies have also adopted strategies such as expanding indications, accelerating clinical development, and differentiated layout to enhance product competitiveness
.
Industrial Securities stated in its research report that in the future, China's innovative drug research and development will require the participation of various pharmaceutical companies
.
With the development and maturity of more important targets and technology platforms, on the basis of in-depth layout, more competitive R&D needs to be done-with "differentiation" and "unmet clinical needs" as the two main lines, from In the early stage of R&D layout, fierce homogenization competition was avoided
.
